⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13348741 | 1.00 | — | — | |
| SCHEMBL4281372 | 1.00 | — | — | |
| SCHEMBL11477583 | 0.75 | — | — | |
| SCHEMBL14344763 | 0.75 | — | — | |
| SCHEMBL10144671 | 0.75 | — | — | |
| SCHEMBL5878479 | 0.74 | — | — | |
| SCHEMBL9353823 | 0.74 | — | — | |
| SCHEMBL8850935 | 0.72 | POLB (0.33) | — | |
| SCHEMBL8850949 | 0.72 | POLB (0.33) | — | |
| SCHEMBL19853529 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268691-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3222614-B1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10626085-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2020-04-21 | — | — | US | disclosed |
| WO-2019067587-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20180044283-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3222614-A2 | BIGUANIDE COMPOUND AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| EP-1370525-B1 | BIGUANIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7285681-B2 | Biguanide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2007-10-23 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
| US-20040092495-A1 | Biguanide derivatives | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1370525-A1 | BIGUANIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074740-A1 | BIGUANIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |